Elanco Animal Health Inc (N:ELAN)
Business Focus: Veterinary Drugs
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 2500 Innovation Way N GREENFIELD IN 46140-9163 |
| Tel: | N/A |
| Website: | https://www.elanco.com |
| IR: | See website |
| Key People | ||
| Jeffrey N. Simmons President, Chief Executive Officer, Director | David A. Urbanek Executive Vice President - Manufacturing and Quality | Todd S. Young Chief Financial Officer, Executive Vice President |
| Shiv O'Neill Executive Vice President, General Counsel, Company Secretary | David S. Kinard Executive Vice President, Human Resources, Corporate Communications and Administration | Timothy J. Bettington Executive Vice President - Corporate Strategy and Market Development |
| Ramiro M. Cabral Executive Vice President , President of Elanco International | Ellen de Brabander Executive Vice President - Innovation and Regulatory and Business Development | Rajeev Modi Executive Vice President - U.S. Pet Health and Global Digital Transformation | Jose Manuel Correia de Simas Executive Vice President, U.S. Farm Animal Business |
| Business Overview |
| Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Elanco Animal Health Inc revenues increased less than 1% to $4.42B. Net loss increased from $78M to $1.23B. Revenues reflect Farm Animal segment increase of 2% to $2.27B, United States segment increase of 1% to $1.98B, also reflect Pet Health segment decrease of 2% to $2.1B, Contract Manufacturing segment decrease of 22% to $42M, International segment decrease of less than 1% to $2.43B. |
| Employees: | 9,300 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $12,057M as of Dec 31, 2023 |
| Annual revenue (TTM): | $4,417M as of Dec 31, 2023 |
| EBITDA (TTM): | $1,020M as of Dec 31, 2023 |
| Net annual income (TTM): | -$1,231M as of Dec 31, 2023 |
| Free cash flow (TTM): | $117.00M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $5,422M as of Dec 31, 2023 |
| Shares outstanding: | 494,097,056 as of Apr 11, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.